Melanotan I (Afamelanotide): MC1R-Selective Pigmentation Research

Melanotan I, now known by its INN as afamelanotide, is a linear synthetic analogue of α-MSH with selective affinity for the MC1R melanocortin receptor subtype. Unlike Melanotan II, it lacks significant activity at MC3R and MC4R, resulting in a more targeted pharmacological profile focused on pigmentation without the appetite, sexual, or CNS effects associated with the non-selective analogue.

Structure and Selectivity

Afamelanotide (Scenesse®) has the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, which preserves the linear structure of α-MSH with key substitutions: norleucine replaces methionine for oxidative stability, and D-phenylalanine at position 7 increases receptor affinity approximately 100-fold over native α-MSH. The linear structure (versus MT-II's cyclic lactam) contributes to its MC1R selectivity profile, as the conformational constraints of cyclisation are not present.

Clinical Development and Regulatory Approval

Afamelanotide was developed by Clinuvel Pharmaceuticals (formerly EpiTan) following early University of Arizona research. It has undergone the most extensive clinical development of any melanocortin peptide, progressing through Phase I, II, and III trials across multiple indications:

• Erythropoietic protoporphyria (EPP): EPP is a rare disorder caused by ferrochelatase enzyme deficiency, leading to phototoxic protoporphyrin IX accumulation. Patients experience severe, disabling pain on sunlight exposure. Two Phase III RCTs (Langendonk et al., NEJM 2015; Wensink et al.) demonstrated that monthly subcutaneous implants of 16 mg afamelanotide significantly extended tolerable sun exposure time and reduced phototoxic episodes versus placebo. Based on this data, Scenesse received EMA approval in 2014 and Australian TGA approval, and FDA approval in 2019.
• Solar urticaria and polymorphous light eruption: Smaller Phase II trials demonstrated benefit in these additional photodermatological conditions.
• Vitiligo: Phase II trials examining afamelanotide combined with narrowband UV-B phototherapy showed significantly faster and more complete repigmentation versus UV-B alone (Lim et al., JAMA Dermatology 2015).

MC1R Pharmacology

MC1R is expressed primarily on epidermal melanocytes and regulates the balance between eumelanin (brown/black, UV-protective) and phaeomelanin (yellow/red, less UV-protective) synthesis. MC1R agonism by afamelanotide shifts this balance markedly toward eumelanin production. In fair-skinned individuals (MC1R variant carriers), this shift is particularly pronounced as baseline MC1R signalling is reduced.

Beyond melanocytes, MC1R is expressed on keratinocytes, Langerhans cells, and various immune cells, suggesting broader roles in cutaneous immune regulation. Research into afamelanotide's anti-inflammatory and photoprotective mechanisms beyond simple pigmentation is ongoing.

DNA Repair and Photoprotection

Afamelanotide's photoprotective effect extends beyond increased melanin production. Research has demonstrated MC1R-dependent enhancement of nucleotide excision repair (NER) capacity in melanocytes, improving UV-induced DNA damage resolution. This is particularly relevant in the context of MCR1 loss-of-function variants (common in fair-skinned populations) that impair NER as well as eumelanin synthesis.

Research Applications

Afamelanotide's well-characterised pharmacology and approved clinical status make it a valuable reference compound for in-vitro melanocyte biology research, MC1R receptor studies, and photoprotection investigations. Research-grade material provides a consistent chemical reference for receptor binding assays, melanogenesis pathway studies, and comparison with novel melanocortin analogues under development.